April 5 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales there of its biosimilar version of AbbVie’s blockbuster arthritis treatment ...
Seattle-based Sana Biotechnology Inc. (Nasdaq: SANA) is losing its research and development lead. In a Thursday filing with ...
The Westchester-based unit of New Jersey-based Kenvue is closing its corporate headquarters at 6080 West Center Drive to ...
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...
Amgen, with its obesity candidate MariTide and other promising treatments in its pipeline, could potentially surpass Eli Lilly in the obesity market. Amgen's stock is undervalued compared to Eli ...
ANNOUNCER: 'Think Tank' has been made possible by Amgen, arecipient of the Presidential ... you have the whole vision laid out justas it was in the 1960s. But the 1960s were a crucial point ...
April 4 (Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due ... with the same prices as Boehringer and Amgen, whose Amjevita was the first Humira ...
(Reuters) - Boehringer Ingelheim on Thursday said it will lay off some of its U.S. salesforce due to poor sales ... its biosimilar Hyrimoz with the same prices as Boehringer and Amgen, whose Amjevita ...